Rocket One Inc

Análisis de la acción Rocket One Inc (RKTO)

$0.407

+0.005 (+1.12%)Al cierre

Loading chart…
Máximo
0.425
Apertura
0.402
Precio medio ponderado por volumen
0.41
Volumen
122.17K
Capitalización
—
Mínimo
0.391
Importe
49.79K
EV/EBITDA, TTM
0.00

Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells.

Análisis de IA of Rocket One Inc (RKTO)

Vender

Rocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.

Métricas de valoración

El PER previsto actual de Rocket One Inc (RKTO) es 0.00, frente a su media de 5 años de .

PER previsto

Media 5A P/E
P/E actual
0.00

EV/EBITDA previsto

Media 5A EV/EBITDA
EV/EBITDA actual
0.00

Precio/ventas previsto

Media 5A P/S
P/S actual
0.00

Cronología de eventos

2026-11-03 (ET)

08:30:00

Hoth Therapeutics Ends Phase 2a Trial of HT-001 Early

2026-10-13 (ET)

16:30:00

Rocket One Signs Research Agreement with Virginia Commonwealth University

2026-10-06 (ET)

08:30:00

Rocket One Signs Patent License Agreement with Air Force

2026-09-22 (ET)

08:30:00

Rocket One Acquires 100% Membership Interests of Tracer Drone Technologies

2026-08-11 (ET)

08:30:00

Rocket One Joins Seagate Partner Program

Noticias

Preguntas frecuentes sobre RKTO, respondidas por Alphio AI

Rocket One Inc. is an artificial intelligence (AI) semiconductor infrastructure company. The Company is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic artificial intelligence (AI) chip technology designed for radiation-tolerant, energy-constrained environments such as low-earth orbit, deep-space platforms, and defense systems. It operates through two segments, which include Biopharmaceutical and AI semiconductor infrastructure. It is also focused on a nanomagnetic matrix multiplier, Skyrmion Spintronic memory, and Swarm Stage AI. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and its glial cell line derived neurotrophic factor (GDNF)-based metabolic program. The HT-001 is used to treat epidermal growth factor receptor (EGFR)-induced skin disorders. The HT-KIT drug is used to treat the receptor tyrosine kinase KIT in mast cells. It operates in the Healthcare sector.

Rocket One Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $0.41, which is down 70.11% year-to-date. The RSI is at an extremely low 17.995, indicating oversold conditions but also potential further declines. The company has reported negative net income for multiple quarters, with a recent loss of $3,832,651 in Q2 2026, and a forward P/E ratio of 0 suggests that earnings are not expected to improve in the near term. The main risk is the ongoing negative sentiment in the market, as evidenced by a 5-day change of -16.48% and a 20-day change of -37.39%.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar